Gene expression preferentially regulated by tamoxifen in breast cancer cells and correlations with clinical outcome

Cancer Research

Volumn 66, Issue 14, 2006, Pages 7334-7340

  Frasor, Jonna ^a   Chang, Edmund C ^a   Komm, Barry ^b   Lin, Chin Yo ^c   Vega, Vinsensius B ^c   Liu, Edison T ^c   Miller, Lance D ^c   Smeds, Johanna ^d   Bergh, Jonas ^b   Katzenellenbogen, Benita S ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^b PFIZER INC   (United States)

^c GENOME INSTITUTE OF SINGAPORE   (Singapore)

^d KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CYCLOHEXIMIDE; DACTINOMYCIN; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FULVESTRANT; RALOXIFENE; TAMOXIFEN;

ADJUVANT THERAPY; ARTICLE; BREAST CANCER; CANCER CELL; CANCER RECURRENCE; CANCER RESISTANCE; CELL STRAIN MCF 7; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG EFFECT; DRUG INHIBITION; DRUG SENSITIVITY; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MARKER GENE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT OUTCOME; UPREGULATION;

BREAST NEOPLASMS; CELL LINE, TUMOR; COHORT STUDIES; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASM RECURRENCE, LOCAL; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN; TREATMENT OUTCOME;

EID: 33746908103     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-4269     Document Type: Article

References (50)

1. Osborne CK, Zhao H, Fuqua SA. Selective estrogen receptor modulators: structure, function, and clinical use. J Clin Oncol 2000;18:3172-86.
2. Katzenellenbogen BS, Montano MM, Ediger TR, et al. Estrogen receptors: selective ligands, partners, am distinctive pharmacology. Recent Prog Horm Res 2000;55:163-93: discussion 94-5.
3. Fisher R, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371-88.
4. Riggs BL, Hartmann LC. Selective estrogen-receptor modulators-mechanisms of action and application to clinical practice. N Engl J Med 2003;348:618-29.
5. Cicatiello L, Scafoglio C, Altucci L, et al. A genomic view of estrogen actions in human breast cancer cells by expression profiling of the hormone responsive transcriptome. J Mol Endocrinol 2004;32 719-75.
6. Frasor J, Danes JM, Komm B, Chang KC, Lyttle CR, Katzenellenbogen BS. Profiling of estrogen up-and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. Endocrinology 2003;144 4562-74.
7. Lin CY, Strom A, Vega VB, et al. Discovery of estrogen receptor α target genes and response elements in breast tumor cells. Genome Biol 2004;5:R66-18.
8. Frasor J, Stossi F, Danes JM, Komm B, Lyttle CH, Katzenellenbogen BS. Selective estrogen receptor modulators: discrimination of agonistic versus antagonistic activities by gene expression profiling in breast cancer cells. Cancer Res 2004;64:1522-33.
9. Hodges LC, Cook JD, Lobenhofer FK, et al. Tamoxifen functions as a molecular agonist inducing cell cycle-associated genes in breast cancer cells. Mol Cancer Res 2003;1:300-11.
10. Shang Y, Brown M. Molecular determinants for the tissue specificity of SERMs. Science 2002;295:2465-8.
11. Katzenellenbogen BS, Katzenellenbogen JA. Defining the "S" in SERMs. Science 2002;295:2380-1.
12. Katzenellenbogen BS, Frasor J. Therapeutic targeting in the estrogen receptor hormonal pathway. Semin Oncol 2004;31:28-38.
13. Lazennec G, Alcorn JL, Katzenellenbogen BS. Adenovirus-mediated delivery of a dominant negative estrogen receptor gene abrogates estrogen-stimulated gene expression and breast cancer cell proliferation. Mol Endocrinol 1999;13:969-80.
14. Wu Z, Irizarry RA, Gentleman H, Martinez-Murillo F, Spencer F. A model-based background adjustment for oligonucleotide expression arrays. J Am Stat Assoc 2004;99:909-17.
15. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 2001;98:5116-21.
16. Choi I, Ko C, Park-Sarge OK, et al. Human estrogen receptor β-specific monoclonal antibodies: characterization and use in studies of estrogen receptor β protein expression in reproductive tissues. Mol Cell Endocrinol 2001;181:139-50.
17. Bergh J, Norberg T, Sjogren S, Lindgren A, Holmberg L. Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nat Med 1995;1:1029-34.
18. Sjogren S, Inganas M, Norberg T, et al. The p53 gent in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry. J Nat Cancer Inst 1996;88:173-82.
19. Miller LD, Smeds J, George J, et al. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci U S A 2005;102 13550-5.
20. Kumar R, Kobayashi T, Warner GM, et al. A novel immediate early response gene, IEX-1, is induced by ultraviolet radiation in human keratinocytes. Biochem Biophys Res Commun 1998;253:336-41.
21. Segev DL, Hoshiya Y, Stephen AE, et al. Mullerian inhibiting substance regulates NFκB signaling and growth of mammary epithelial cells in vivo. J Biol Chem 2001;276:26799-806.
22. Paech K, Webb P, Kuiper GG, et al. Differential ligand activation of estrogen receptors ERα and ERβ at AP1 sites. Science 1997;277:1508-10.
23. Quaedackers ME, Van Den Brink CE, Wissink S, et al. 4-Hydroxytamoxifen trans-represses nuclear factor-κB activity in human osteoblastic U2-OS cells through estrogen receptor (ER)α, and not through ERβ. Endocrinology 2001;142:1156-66.
24. Monroe DG, Secreto FJ, Subramaniam M, Getz BJ, Khosla S, Spelsberg TC. Estrogen receptor α and β heterodimers exert unique effects on estrogen- and tamoxifen-dependent gene expression in human U2OS osteosarcoma cells. Mol Endocrinol 2005;19:1555-68.
25. Tremblay A, Tremblay GB, Labrie F, Giguere V. Ligand-independent recruitment of SRC-1 to estrogen receptor β through phosphorylation of activation function AF-1. Mol Cell 1999;3:513-9.
26. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687-717.
27. Ali S, Coombes RC. Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer 2002;2:101-12.
28. Schiff R, Massarweh S, Shou J, Osborne CK. Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response. Clin Cancer Res 2003;9:447-545.
29. Brzozowski AM, Pike AC, Dauter Z, et al. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 1997;389:753-8.
30. Shiau AK, Barstad D, Loria PM, et al. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 1998;95:927-37.
31. Pike AC, Brzozowski AM, Hubbard RE, et al. Structure of the ligand-binding domain of oestrogen receptor β in the presence of a partial agonist and a full antagonist. EMBO J 1999;18:4608-18.
32. McInerney EM, Katzenellenbogen BS. Different regions in activation function-1 of the human estrogen receptor required for antiestrogen- and estradiol-dependent transcription activation. J Biol Chem 1996;271:24172-8.
33. Shang Y, Hu X, DiRenzo J, Lazar MA, Brown M. Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription. Cell 2000;103:843-52.
34. Stossi F, Barnett DH, Frasor J, Komm B, Lyttle CR, Katzenellenbogen BS. Transcriptional profiling of estrogen-regulated gene expression via estrogen receptor (ER) α or ERβ in human osteosarcoma cells: distinct and common target genes for these receptors. Endocrinology 2004;145:3473-86.
35. Kian Tee M, Rogatsky I, Tzagarakis-Foster C, et al. Estradiol and selective estrogen receptor modulators differentially regulate target genes with estrogen receptors α and β. Mol Biol Cell 2004;15:1262-72.
36. Hall JM, McDonnell DP. The estrogen receptor β-isoform (ERβ) of the human estrogen receptor modulates ERα transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens. Endocrinology 1999;140:5566-78.
37. Heldring N, Nilsson M, Buehrer B, Treuter E, Gustafsson JA. Identification of tamoxifen-induced coregulator interaction surfaces within the ligand-binding domain of estrogen receptors. Mol Cell Biol 2004;24:3445-59.
38. Saji S, Hirose M, Toi M. Clinical significance of estrogen receptor β in breast cancer. Cancer Chemother Pharmacol 2005;56 Suppl 1:21-6.
39. Yoshikawa H, Matsubara K, Qian GS, et al. SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity. Nat Genet 2001;28:29-35.
40. Panagopoulos I, Pandis N, Thelin S, et al. The FHIT and PTPRG genes are deleted in benign proliferative breast disease associated with familial breast cancer and cytogenetic rearrangements of chromosome band 3p14. Cancer Res 1996;56:4871-5.
41. Macdonald N, Welburn JP, Noble ME, et al. Molecular basis for the recognition of phosphorylated and phosphoacetylated histone h3 by 14-3-3. Mol Cell 2005;20:199-211.
42. Ogihara T, Isobe T, Ichimura T, et al. 14-3-3 Protein binds to insulin receptor substrate-1, one of the binding sites of which is in the phosphotyrosine binding domain. J Biol Chem 1997;272;25267-74.
43. Oksvold MP, Huitfeldt HS, Langdon WY. Identification of 14-3-3ζ as an EGF receptor interacting protein. FEBS Lett 2004;569:207-10.
44. Wilker E, Yaffe MB. 14-3-3 Proteins-a focus on cancer and human disease. J Mol Cell Cardiol 2004;37:633-42.
45. van't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530-6.
46. van de Vijver MJ, He YD, van't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002;347:1999-2009.
47. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351:2817-26.
48. Ma XJ, Wang Z, Ryan PD, et al. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 2004;5:607-16.
49. Jansen MP, Foekens JA, van Staveren IL, et al. Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling. J Clin Oncol 2005;23:732-40.
50. Howell A, Cuzick J, Baum M, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005;365:60-2.